EUVIMEDEUVIMED entdecken
Crossref

Oncologic Outcomes with Neoadjuvant Chemotherapy and Breast Conservation for MRI Occult Breast Cancer

Brady Laughlin, Sima Ehsani, Pavani Chalasani, Victor Gonzalez

Archives of Breast Cancer · 01.08.2018

DOI: 10.19187/abc.201853138-143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Breast Cancer, erschienen am 01.08.2018. Verfasst von Brady Laughlin und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Occult primary breast cancer is a presentation of breast cancer involving lymph nodes without an identified primary tumor within the breast. Mastectomy with axillary node dissection has been the traditional management. However, reported oncologic outcomes with mastectomy have been similar to those with breast conserving therapy (axillary surgery and radiotherapy). With the increased sensitivity of MRI and its routine use in the workup of occult breast cancer, the role of mastectomy for occult breast cancer is now even less clear. We report our institutional experienc of neoadjuvant chemotherapy followed by axillary surgery and radiotherapy for women with occult breast cancer.

Methods

We conducted a retrospective review of women diagnosed with isolated metastatic adenocarcinoma to the axilla histologically consistent with breast adenocarcinoma without evidence of a primary breast tumor. Medical records were analyzed to gather pertinent information regarding diagnostic workup, treatment, recurrence, and survival.

Results

We identified seven patients treated in our institution between 2012 and 2017 who met the criteria for primary occult breast cancer. The median age at diagnosis was 63 years old (range 42-71). Subtypes by immunohistochemistry (IHC) were HER-2 positive (3 pts), triple negative (2 pts), and hormone receptor positive/HER-2 negative (2 pts). All patients received neoadjuvant chemotherapy and axillary surgery without mastectomy followed by adjuvant radiotherapy to the breast and regional nodes. Hormone receptor positive patients received adjuvant endocrine therapy. At a median follow-up of 3.5 years, all patients were alive with no local or regional recurrence of disease while one patient developed distant metastases.

Conclusion

A multimodality approach with neoadjuvant chemotherapy can lead to high rates of breast conservation in women with primary occult breast cancer. This approach appears to be oncologically safe.

Schlagwörter

occult breast cancerneoadjuvant chemotherapybreast-conserving surgeryaxillary surgeryadjuvant radiotherapyaxillary lymph node metastasisHER2-positive breast cancertriple-negative breast cancerhormone receptor-positive breast cancerendocrine therapy

Zitieren

APA

Laughlin, B., Ehsani, S., Chalasani, P., & Gonzalez, V. (2018). Oncologic Outcomes with Neoadjuvant Chemotherapy and Breast Conservation for MRI Occult Breast Cancer. Archives of Breast Cancer. https://doi.org/10.19187/abc.201853138-143

Vancouver

Laughlin B, Ehsani S, Chalasani P, Gonzalez V. Oncologic Outcomes with Neoadjuvant Chemotherapy and Breast Conservation for MRI Occult Breast Cancer. Archives of Breast Cancer. 2018. doi:10.19187/abc.201853138-143

BibTeX
@article{Laughlin2018,
  author = {Laughlin, Brady and Ehsani, Sima and Chalasani, Pavani and Gonzalez, Victor},
  title = {Oncologic Outcomes with Neoadjuvant Chemotherapy and Breast Conservation for MRI Occult Breast Cancer},
  journal = {Archives of Breast Cancer},
  year = {2018},
  doi = {10.19187/abc.201853138-143}
}
Kostenlos starten →